No Data
Zomedica Has Launched Its Third Equine-focused Assay-insulin For Equine Plasma-For Truforma In-Clinic Biosensor Testing Platform
Noble Financial Initiates Zomedica(ZOM.US) With Buy Rating, Announces Target Price $0.25
Zomedica Positioned for Growth With Strategic Acquisitions and Strong Financial Performance: Buy Recommendation
Zomedica to Present at the Sidoti Micro Cap Conference November 14, 2024
Zomedica Corp Posts Increased Revenue Amid Loss
Zomedica Corp. (ZOM) Q3 2024 Earnings Call Transcript Summary
No Data
No Data